SCHEMBL6804201

SCHEMBL6804201

Nc1cccc(Nc2ncccn2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 2/20 0.60
BCR P11274 2/20 0.60
SRC P12931 2/20 0.60
MEN1 O00255 2/20 0.59
LMNA P02545 2/20 0.59
GAA P10253 2/20 0.59
MAPT P10636 2/20 0.59
KMT2A Q03164 2/20 0.59
KDM4E B2RXH2 1/20 0.59
GFER P55789 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
EGFR P00533 2/20 0.57
PRKACA P17612 1/20 0.57
PRKACG P22612 1/20 0.57
PRKACB P22694 1/20 0.57
SYK P43405 3/20 0.57
CDK5 Q00535 1/20 0.54
CAMK2D Q13557 1/20 0.52
CDK4 P11802 1/20 0.52
CDK2 P24941 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24270328 0.85 SYK (0.62) ABL1BCRSRCMEN1LMNA
SCHEMBL11795454 0.83 MEN1 (0.63) ABL1BCRSRCMEN1LMNA
SCHEMBL31302305 0.83 MEN1 (0.63) ABL1BCRSRCMEN1LMNA
SCHEMBL653992 0.83 SYK (0.68) ABL1BCRSRCMEN1LMNA
SCHEMBL5504084 0.82 SYK (0.59) ABL1BCRSRCMEN1LMNA
SCHEMBL24507552 0.81 ABL1 (0.62) ABL1BCRSRCMEN1LMNA
SCHEMBL11584735 0.81 SYK (0.62) ABL1BCRSRCMEN1LMNA
SCHEMBL6804491 0.80 CA12 (0.51) ABL1BCRSRCMEN1LMNA
SCHEMBL2127990 0.80 MAPT (0.86) ABL1BCRSRCMEN1LMNA
SCHEMBL4903508 0.80 ABL1 (0.67) ABL1BCRSRCMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3483155-B1 SPIRO THREE-MEMBERED RING OR SPIRO FIVE-MEMBERED RING PEPTIDE DEFORMYLASE INHIBITOR AND USE THEREOF AS AN ANTI-TUMOUR AGENT GUANGDONG HEBO PHARMACEUTICAL CO LTD (CN) 2022-10-26 EP disclosed
US-10738028-B2 Spiro three-membered ring, spiro five-membered ring peptide deformylase inhibitor and use thereof in antibacteria and anti-tumor RUDONG RUIEN PHARMACEUTICAL TECHNOLOGY CO. LTD (CN) 2020-08-11 US disclosed
US-10738028-B2 Spiro three-membered ring, spiro five-membered ring peptide deformylase inhibitor and use thereof in antibacteria and anti-tumor RUDONG RUIEN PHARMACEUTICAL TECHNOLOGY CO. LTD (CN) 2020-08-11 US disclosed
CN-107362162-B Antitumor application of spirotricyclic and spiropentacyclic peptide deformylase inhibitor 如东瑞恩医药科技有限公司 2019-12-13 CN disclosed
CN-107365303-B Antibacterial application of spirotricyclic and spiropentacyclic peptide deformylase inhibitor 如东瑞恩医药科技有限公司 2019-12-13 CN disclosed
CN-107365302-B Spiro three-membered ring, spirofive-membered ring peptoid deformylase inhibitors 如东瑞恩医药科技有限公司 2019-12-13 CN disclosed
US-20190194165-A1 SPIRO THREE-MEMBERED RING, SPIRO FIVE-MEMBERED RING PEPTIDE DEFORMYLASE INHIBITOR AND USE THEREOF IN ANTIBACTERIA AND ANTI-TUMOR RUDONG RUIEN PHARMACEUTICAL TECHNOLOGY CO. LTD (CN) 2019-06-27 US disclosed
US-20190194165-A1 SPIRO THREE-MEMBERED RING, SPIRO FIVE-MEMBERED RING PEPTIDE DEFORMYLASE INHIBITOR AND USE THEREOF IN ANTIBACTERIA AND ANTI-TUMOR RUDONG RUIEN PHARMACEUTICAL TECHNOLOGY CO. LTD (CN) 2019-06-27 US disclosed
EP-3483155-A1 SPIRO THREE-MEMBERED RING, SPIRO FIVE-MEMBERED RING PEPTIDE DEFORMYLASE INHIBITOR AND USE THEREOF IN ANTIBACTERIA AND ANTI-TUMOUR. Rudong Ruien Pharmaceutical Technology Co., Ltd. (CN) 2019-05-15 EP disclosed
EP-3483155-A1 SPIRO THREE-MEMBERED RING, SPIRO FIVE-MEMBERED RING PEPTIDE DEFORMYLASE INHIBITOR AND USE THEREOF IN ANTIBACTERIA AND ANTI-TUMOUR. Rudong Ruien Pharmaceutical Technology Co., Ltd. (CN) 2019-05-15 EP disclosed
WO-2017193924-A1 SPIRO THREE-MEMBERED RING, SPIRO FIVE-MEMBERED RING PEPTIDE DEFORMYLASE INHIBITOR AND USE THEREOF IN ANTIBACTERIA AND ANTI-TUMOUR. 如东瑞恩医药科技有限公司 2017-11-16 WO disclosed
US-6727245-B2 4-(HETERO)ARYL-3-OXO-3,4-DIHYDROPYRIDO(2,3-B)PYRAZINE DERIVATIVES; PROPHYLACTIC OR THERAPEUTIC TREATMENT OF PHOSPHODIESTERASE IV AND TUMOR NECROSIS FACTOR MEDIATED DISEASES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-04-27 US disclosed
EP-0770079-B1 HETEROBICYCLIC DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2003-02-12 EP disclosed
US-20020107251-A1 Heterobicyclic derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-08-08 US disclosed
US-6426345-B1 PHOSPHODIESTERASE INHIBITORS; ANTIINFLAMMATORY AGENTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-07-30 US disclosed
EP-0920867-A1 Pyrido[2,3-a]pyrazine derivatives as PDE-IV and TNF inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-06-09 EP disclosed
WO-1996001825-A1 HETEROBICYCLIC DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738028-B2 Spiro three-membered ring, spiro five-membered ring peptide deformylase inhibitor and use thereof in antibacteria and anti-tumor PDF, HSPE1, ERAL1 ABL1 4483/4885BCR 50/4885SRC 3665/4885
US-20190194165-A1 SPIRO THREE-MEMBERED RING, SPIRO FIVE-MEMBERED RING PEPTIDE DEFORMYLASE INHIBITOR AND USE THEREOF IN ANTIBACTERIA AND ANTI-TUMOR PDF, HSPE1, ATP5PB ABL1 4580/4885BCR 55/4885SRC 3771/4885
US-20020107251-A1 Heterobicyclic derivatives ARSA, ARRB1, SULT2A1 ABL1 408/4885BCR 1628/4885SRC 232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.